知镜 Cognispect · 医学文献与研究工作台

Ticagrelor versus prasugrel following PCI in acute coronary syndromes and high-risk coronary artery disease: A meta-analysis of one-year randomized trial outcomes.

Gbreel MI, Badran AS, Robinson D, Ebeid I, Hassan M, Abdelrahman AA, Bodanowitz J, Valenta S, Valenta C, Kochev P, Ortak J, Ince H, Balata M.
American heart journal plus : cardiology research and practice · 2026-10-05 · PMID 42892998

文献摘要

Background Guidelines recommend potent P2Y12 inhibitors over clopidogrel following percutaneous coronary intervention. Whether ticagrelor- or prasugrel-based dual antiplatelet therapy (DAPT) provides superior clinical outcomes following percutaneous coronary intervention (PCI) remains uncertain, particularly across acute coronary syndromes (ACS) and high-risk coronary artery disease (CAD) populations. Methods We searched databases for randomized controlled trials comparing ticagrelor- and prasugrel-based DAPT in patients with CAD undergoing PCI with 1-year follow-up. The primary outcomes were major adverse cardiovascular events (MACE) and all-cause mortality. Secondary outcomes included cardiovascular death, myocardial infarction, stroke, stent thrombosis, and major bleeding. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Sensitivity analyses were performed in ACS populations. Results Three trials randomized a total of 7048 patients. In the primary analysis, prasugrel-based therapy was not associated with a statistically significant reduction in MACE compared with ticagrelor-based therapy (HR = 0.83; 95% CI: 0.67-1.03; p = 0.09). All-cause mortality (HR = 0.86; 95% CI: 0.68-1.08; p = 0.20), cardiovascular death (HR = 0.93; 95% CI: 0.72-1.21; p = 0.60), myocardial infarction (HR = 0.80; 95% CI: 0.56-1.14; p = 0.22), stroke (HR = 1.04; 95% CI: 0.63-1.73; p = 0.87), stent thrombosis (HR = 0.70; 95% CI: 0.45-1.11; p = 0.13), and major bleeding (HR = 0.89; 95% CI: 0.68-1.17; p = 0.41) were comparable between strategies. ACS-restricted sensitivity analyses demonstrated consistent findings across all outcomes. Conclusions Among patients with ACS and high-risk CAD undergoing PCI, current randomized evidence does not establish conclusive superiority between ticagrelor- and prasugrel-based DAPT for 1-year ischemic or bleeding endpoints.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。